Please find attached the file
MOREPENLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Morepen Laboratories' Board approved a Second Addendum to the Business Transfer Agreement (BTA) with its subsidiary Morepen Medipath Limited (MML), revising the appointed date for the Medical Devices Business slump sale transfer to April 1, 2026. The slump sale consideration is Rs. 19,710.12 lakhs (approx. Rs. 197 crore), not less than fair market value per Rule 11UAE of IT Rules, certified by an independent valuer. The transaction is a related party transaction on arm's length basis. The Board also approved audited standalone (net profit Rs. 6,605.75L) and consolidated (net profit after minority interest Rs. 2,031.54L) results with unmodified auditor opinion. A final dividend of Rs. 0.20 per share (face value Rs. 2) was recommended, subject to shareholder approval at AGM.
The Medical Devices Business hive-off represents a significant internal restructuring. Investors should note the company holds 51% of MML, with an additional ~42.89% held by promoter group entities, making this a related party transaction. The deal value of Rs. 197 crore and the shift in appointed date may have near-term accounting and tax implications.